New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

MannKind Corporation (MNKD) vs Taysha Gene Therapies, Inc. (TSHA)

MannKind Corporation and Taysha Gene Therapies, Inc. are both Biotechnology companies. MannKind Corporation and Taysha Gene Therapies, Inc. are of similar size ($1.4B and $1.3B). MannKind Corporation grew revenue faster over the last twelve months: 31.7% against 19.0%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −18.1%) and the higher return on invested capital (0.00% vs −2.58%). Across the 16 metrics below, MannKind Corporation leads on 8 and Taysha Gene Therapies, Inc. on 8.

Valuation

Metric MNKD TSHA Biotechnology median
P/E n/m n/m 8.26
P/S 3.05 129.80 9.20
P/B n/m 4.29 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 102.26 n/m 0.67
EV/Sales 3.84 97.97 9.05
Earnings yield (5.84%) (11.31%) (34.24%)
Free cash flow yield (6.22%) (9.45%) (24.77%)

Profitability

Metric MNKD TSHA Biotechnology median
Gross margin 75.76% 100.00% 70.18%
Operating margin (2.88%) 0.00% 0.00%
Net margin (18.10%) 0.00% 0.00%
Free cash flow margin (18.97%) 0.00% 0.00%
Return on equity 182.90% (54.18%) (51.58%)
Return on assets (12.29%) (41.52%) (45.91%)
Return on invested capital (2.58%) 0.00% 0.00%

Growth

Metric MNKD TSHA Biotechnology median
Revenue growth (TTM) 31.74% 18.96% 7.20%
EPS growth (last fiscal year) (80.00%) 5.56% 29.04%
Revenue growth, 5-year CAGR 39.89% — 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNKD TSHA Biotechnology median
Debt to equity (11.33) 0.13 0.00
Current ratio 2.22 18.56 4.83
Net debt to EBITDA 5.32 2.47 1.01

Dividend

Metric MNKD TSHA Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric MNKD TSHA Biotechnology median
Market cap 1.35b 1.26b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack